Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial - 19/06/14
, E. Magnus Ohman, MB, ChB b, c, Benjamin Neely, MS b, Peter Clemmensen, MD d, Piyamitr Sritara, MD e, Dmitry Zamoryakhin, MD f, Paul W. Armstrong, MD g, Dorairaj Prabhakaran, MD, DM, MSc h, Harvey D. White, MB, ChB, DSc i, Keith A.A. Fox, MB, ChB j, Paul A. Gurbel, MD k, Matthew T. Roe, MD, MHS b, cfor the TRILOGY ACS Investigators
Résumé |
Background |
To further explore the impact of smoking on antiplatelet activity and treatment response, we evaluated time-dependent relationships between smoking status with on-treatment platelet reactivity and clinical outcomes for prasugrel vs. clopidogrel in patients with acute coronary syndromes managed medically without revascularization.
Methods and Results |
A total of 7062 patients aged <75 years from the primary TRILOGY ACS cohort randomized to prasugrel vs. clopidogrel were evaluated through 30 months by baseline and time-dependent smoking status with adjusted proportional-hazards models. A total of 1613 participants (23%) were included in a platelet function sub-study evaluating serial P2Y12 reaction unit (PRU) measurements. Current smokers (n = 1566 [22%]) at baseline had fewer comorbidities compared with non-smokers; nearly half quit smoking during follow-up. Although median on-treatment PRU values were lower with prasugrel vs. clopidogrel, persistent smokers had lower serial PRU values in both treatment groups compared with non-smokers, with no differential interaction of treatment response by smoking status. The frequency of cardiovascular death, myocardial infarction, or stroke in current smokers was significantly lower with prasugrel (11.7%) vs. clopidogrel (18.6%), but there was no difference in non-smokers (13.8% vs. 13.7%), with significant interaction between treatment and baseline smoking status (P = .0002). Bleeding events occurred more frequently in prasugrel-treated patients with no significant interaction between treatment and baseline smoking status.
Conclusions |
Among medically managed ACS patients <75 years of age, the risk of ischemic outcomes was significantly reduced with prasugrel vs. clopidogrel among smokers vs. non-smokers. No interaction between on-treatment platelet reactivity and smoking status was found.
Le texte complet de cet article est disponible en PDF.Plan
| Marc Cohen, MD. Clin. Inv., AIHD served as guest editor for this article. |
|
| Source of funding: The TRILOGY ACS study was funded by Daiichi Sankyo and Eli Lilly. |
|
| RCT# NCT00699998 |
Vol 168 - N° 1
P. 76 - juillet 2014 Retour au numéro
Article précédent
- Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
- Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James
- Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial
- Emerson C. Perin, Ricardo Sanz-Ruiz, Pedro L. Sánchez, José Lasso, Rosa Pérez-Cano, Juan C. Alonso-Farto, Esther Pérez-David, Maria Eugenia Fernández-Santos, Patrick W. Serruys, Henrick J. Duckers, Jens Kastrup, Steven Chamuleau, Yi Zheng, Guilherme V. Silva, James T. Willerson, Francisco Fernández-Avilés
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?